Ontology highlight
ABSTRACT: Unlabelled
The adaptive nature of artificial intelligence (AI), with its ability to improve performance through continuous learning, offers substantial benefits across various sectors. However, current regulatory frameworks are not intended to accommodate this adaptive nature, and they have prolonged approval timelines, sometimes exceeding one year for some AI-enabled devices. This creates significant challenges for manufacturers who must deal with lengthy waits and submit multiple approval requests for AI-enabled device software functions as they are updated. In response, regulatory agencies like the US Food and Drug Administration (FDA) have introduced guidelines to better support the approval process for continuously evolving AI technologies. This article explores the FDA's conc
SUBMITTER: Carvalho E
PROVIDER: S-EPMC12577744 | biostudies-literature | 2025 Oct
REPOSITORIES: biostudies-literature